Fig 3.

Outcomes in patients who received latent membrane protein (LMP) –cytotoxic T lymphocytes (CTLs) as treatment for relapsed or refractory disease. (A) Distribution of clinical responses among 21 patients. (B) Increased proportion of responding versus nonresponding patients had CTLs with specific activity against LMP1 by interferon gamma enzyme-linked immunospot assay. (C) This relationship was not apparent when analysis was based on CTLs with LMP2-specific activity. (D) Two-year event-free survival for patients treated in LMP2-CTL protocol (n = 8) versus LMP1/2-CTL protocol (n = 13; P = .626). (E) Cumulative risk of death resulting from lymphoma or other causes. CR, complete response; NR, no response; PR, partial response; SFC, spot-forming cell.